

Arcadia Biosciences Inc

16:54 06 Nov 2019

Arcadia Biosciences CEO says firm laying foundation for rapid revenue growth as it posts 3Q results

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO told shareholders on Wednesday that the company is making strategic headway in its mission to enhance the quality and nutritional content of crops.

In a statement accompanying the Davis, California-based company's third-quarter results, CEO Matthew Plavan told investors that Arcadia achieved important progress during the quarter in both product commercialization and continuing research and development in each of its three strategic crop categories - hemp, wheat and soy.

"We continue to lay the foundations for rapid revenue growth, across multiple product lines in 2020 and beyond, with notable acceleration of our hemp genetic innovations to enhance the enterprise value of our growing germplasm estate," Plavan told investors.

READ: Arcadia Biosciences wins wheat order, reports significant expansion in GoodWheat harvest acres

The results come amidst signs of progress towards cannabis legalization in the US. Last week the US Department of Agriculture issued a new ruling clarifying the content of the 2018 Farm Bill, a key step in legal hemp cultivation in the country.

The new ruling outlined the requirement for states to regulate procedures testing hemp crops for THC, the psychoactive compound in the crop. Any hemp crop that exceeds 0.3% THC must be disposed of, according to the latest regulations.

The move increases the importance of Arcadia's hemp research currently underway in Hawaii and California, Plavan said in a statement.

"We are bringing modern breeding science and genomics technology to develop high-quality non-GM hemp varieties with improved uniformity, stability, resiliency and yield, enabling farmers to maximize the value and profitability of this newly-legal crop."

READ: Arcadia Biosciences is here to grow a healthier world

Arcadia is projecting its revenue figures to exceed \$10 million in 2020 and \$30 million in 2021. Based upon this revenue growth, the company expects to generate net cash from operating activity by mid to late 2021, with sustained profitability thereafter, it laid out in a statement.

Plavan added: "As an agricultural technology company accustomed to working within USDA and the US Food and Drug Administration (FDA) regulated sectors, we welcome these rules, which enable us to move forward with our plans for both cannabidiol (CBD) production and hemp germplasm improvement."

Price: 4.96

Market Cap: \$42.88 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: RKDA

Listing: NASDAQ

52 week	High	Low
	10.4	1.85

Sector: Agribusiness

Website: arcadiabio.com

Company Synopsis:

Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.

action@proactiveinvestors.com

Focus on growth

During the third quarter ended September 30, the company posted revenue of \$392,000, up from the \$370,000 figure it posted over the same period a year prior.

Net loss for the period was \$14.2 million, or \$2.04 per share, which the company attributed to stock pressure.

The CEO told shareholders that the company is "working hard every day to bring consumers new and improved healthy food options, while maintaining a single-minded focus: profitable growth."

Shares of Arcadia closed Wednesday at \$5.77 on the NASDAQ.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).